Vimarsana
Biggest News Aggregation in the World

Page 40 - Nuclear Export News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nuclear Export Today - Breaking & Trending Today

Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting - Vimarsana News

Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting

Published: December 14, 2021

/PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering,...

Source: prnewswire.com
Related Topics:
United StatesGeorgia World Congress CenterSouth KoreaHuiqiang HuangKevin LynchJay MeiAsia PacificPeter QianKaryopharm Press Release On NovKaryopharm Therapeutics IncAntengene CorporationSun Yat Sen University Affiliated Cancer HospitalDrug AdministrationSelective Inhibitor Of NuclearAntengene Corporation LimitedLymphoma CenterChief Medical OfficerChief Executive OfficerHeavily Pretreated PatientsPeripheralt Cell LymphomaT Cell LymphomaPreliminary ResultsSingle Arm Phase Ib StudyGeorgia World CongressKaryopharm Therapeutics
Karyopharm Announces Presentation of Updated Phase 2 Selinexor Data in Patients with Myelofibrosis at the American Society of Hematology 2021 Annual Meeting and Exposition - Vimarsana News

Karyopharm Announces Presentation of Updated Phase 2 Selinexor Data in Patients with Myelofibrosis at the American Society of Hematology 2021 Annual Meeting and Exposition

Published: December 11, 2021

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced an...

Source: prnewswire.com
Related Topics:
United StatesSrinivas TantravahiSharon ShachamSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncEuropean CommissionUniversity Of UtahDrug AdministrationAmerican Society Of HematologyExchange CommissionEuropean UnionKaryopharm Selective Inhibitor Of Nuclear ExportInformation DepartmentKaryopharm TherapeuticsSelective InhibitorNuclear ExportAmerican SocietyChief Scientific OfficerEvaluating Single Agent SelinexorMyelofibrosis RefractoryMyeloproliferative SyndromesNew Drug ApplicationMedical InformationFetal ToxicityPrivate Securities Litigation Reform Act
Karyopharm Announces Presentation of Updated Phase 2 Selinexor Data in Patients with Myelofibrosis at the American Society of Hematology 2021 Annual Meeting and Exposition - Vimarsana News

Karyopharm Announces Presentation of Updated Phase 2 Selinexor Data in Patients with Myelofibrosis at the American Society of Hematology 2021 Annual Meeting and Exposition

Published: December 11, 2021

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced an...

Source: prnewswire.com
Related Topics:
United StatesSrinivas TantravahiSharon ShachamSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncEuropean CommissionUniversity Of UtahDrug AdministrationAmerican Society Of HematologyExchange CommissionEuropean UnionKaryopharm Selective Inhibitor Of Nuclear ExportInformation DepartmentKaryopharm TherapeuticsSelective InhibitorNuclear ExportAmerican SocietyChief Scientific OfficerEvaluating Single Agent SelinexorMyelofibrosis RefractoryMyeloproliferative SyndromesNew Drug ApplicationMedical InformationFetal ToxicityPrivate Securities Litigation Reform Act
Karyopharm Announces the Appointment of Peter K Honig, MD, MPH to its Board of Directors - Vimarsana News

Karyopharm Announces the Appointment of Peter K Honig, MD, MPH to its Board of Directors

Published: December 6, 2021

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the...

Source: prnewswire.com
Related Topics:
United StatesMikael DolstenPeterk HonigBarrye GreeneOffice Of Drug SafetyAlopexx EnterprisesDrug Information AssociationAmerican Society For Clinical PharmacologyMedicine ConsortiumHead Of Global Regulatory AffairsKaryopharm Selective Inhibitor Of Nuclear ExportEuropean UnionKaryopharm Therapeutics IncMerck Research LaboratoriesInternational Conference On HarmonisationSteering CommitteeDrug AdministrationEuropean CommissionColumbia UniversityPrnewswire Karyopharm Therapeutics IncExchange CommissionGroup Head Of DevelopmentCentre Of Regulatory ExcellenceLead DirectorSenior Vice President
Karyopharm Announces Dosing of First Patient in a New Phase 2 Study Evaluating Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis - Vimarsana News

Karyopharm Announces Dosing of First Patient in a New Phase 2 Study Evaluating Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis

Published: December 6, 2021

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing...

Source: prnewswire.com
Related Topics:
United StatesEmilia RomagnaSrinivas TantravahiSharon ShachamInstituto Scientifico RomagnoloGiovanni MartinelliSelective Inhibitor Of Nuclear ExportUniversity Of Utah HospitalKaryopharm Therapeutics IncEuropean CommissionDrug AdministrationPrnewswire Karyopharm Therapeutics IncAmerican Society Of HematologyExchange CommissionResearch HematologistKaryopharm Selective Inhibitor Of Nuclear ExportInformation DepartmentSelective InhibitorNuclear ExportIndependent ReviewLead Principal InvestigatorAlessandro LucchesiProfessor Giovanni MartinelliChief ScientificUtah Hospital